Advertisement

The Complex Problem of Treatment

  • D. A. W. Johnson

Abstract

Although the presence of depressive mood disorders in schizophrenia has been recognised since the days of Kraepelin and Bleuler the prevalence of mood disorders and the resultant morbidity has been assessed only recently. A review of the literature suggests a frequency of 15–50 percent over 9–24 months (Table 1).

Keywords

Mood Disorder Chronic Schizophrenia Affective Symptom Neuroleptic Drug Acute Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brockington I F, Kendell R E, Wainwright S, Hillier VF, Walker J: The distinction between affective psychoses and schizophrenia. Br J Psychiatry 125: 243–248, 1979.CrossRefGoogle Scholar
  2. 2.
    Brockington I F, Leff JP: Schizo-affective psychosis: definitions and incidence. Psychol Med 9: 91–99, 1979.PubMedCrossRefGoogle Scholar
  3. 3.
    Cheadle AJ, Freeman HL, Korer J: Chronic schizophrenic patients in the community. Br J Psychiatry 132: 211–227.Google Scholar
  4. 4.
    Conrad K: Die beginnende schizophrenia: versuch einer gestaltanalyse des wahns. Thieme: Stuggart. p. 315, 1958.Google Scholar
  5. 5.
    Delva NJ, Letemendia FJJ: Lithium treatment in schizophrenia and schizo-affective disorders, in Contemporary Issues in Schizophrenia, Edited by Kerr A, Snaith P. Gaskell, London 381–396, 1986.Google Scholar
  6. 6.
    Falloon O, Watt DC, Shepherd M: A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 8: 59–70, 1978.Google Scholar
  7. 7.
    Galdi J, Rieder RO, Silber D, Bonato RR: Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychol Med 11: 713–728, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Galdi J: Depression ‘revealed’ in schizophrenia: A discussion, in Contemporary Issues in Schizophrenia, ed. Kerr A, Snaith P, Gaskell, London 462–466, 1986.Google Scholar
  9. 9.
    Helmchen H, Hippius H: Depressive syndrome im verlauf neuroleptischer therapie. Nervenarzt 38: 455–458, 1967.PubMedGoogle Scholar
  10. 10.
    Hirsch SR: Depression in schizophrenia, in Schizophrenia, Edited by Hirsch SR, Update Publications, London, 1984.Google Scholar
  11. 11.
    Hirsch SR: Depression ‘revealed’ in schizophrenia, in Contemporary Issues in Schizophrenia, Edited by Kerr A, Snaith P, Gaskell, London, 459–461 and 467–469, 1986.Google Scholar
  12. 12.
    Hirsch SR, Gaind A, Rohde PD, Stevens BC, Wing JK: Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: a double-blind placebo trial. Brit Med J, i, 633–637, 1973.Google Scholar
  13. 13.
    Johnson DAW: Studies of depressive symptoms in schizophrenia. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  14. Johnson DAW: Prevalence of depression and its possible causes. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  15. Johnson DAW: A two year longitudinal study of symptoms. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  16. Johnson DAW: A double-blind trial of orphenadrine against placebo. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  17. Johnson DAW: A double-blind trial of nortriptyline for depression in chronic schizophrenia. Br J Psychiatry 139: 89–101, 1981.PubMedCrossRefGoogle Scholar
  18. 14.
    Johnson DAW, Ludlow JM, Street K, Taylor RDW: Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilized out-patients with schizophrenia. Br J Psychiatry 151: 634–638, 1987.PubMedCrossRefGoogle Scholar
  19. 15.
    Johnson DAW: The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 152: 320–323, 1988.PubMedCrossRefGoogle Scholar
  20. 16.
    Knights A, Hirsch SR: Revealed depression and drug treatment for schizophrenia. Arch Gen Psychiatry 38: 806–811, 1981.PubMedCrossRefGoogle Scholar
  21. 17.
    McGlashan TH, Carpenter WT: Postpsychotic depression in schizophrenia. Arch Gen Psychiatry, 33: 231–239, 1976a.PubMedCrossRefGoogle Scholar
  22. 18.
    McGlashan TH, Carpenter WT: An investigation of the postpsychotic depressive syndrome. Am J Psychiatry, 133: 14–19, 1976b.PubMedGoogle Scholar
  23. 19.
    Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M: Development and prediction of postpsychotic depression in neuroleptic treated schizophrenics. Arch Gen Psychiatry, 39: 197–203.Google Scholar
  24. 20.
    Roy A: Suicide in chronic schizophrenia. Br J Psychiatry, 141: 171–177, 1982.PubMedCrossRefGoogle Scholar
  25. 21.
    Roy A, Thompson R, Kennedy S: Depression in schizophrenia. Br J Psychiatry 142: 465–478, 1983.PubMedCrossRefGoogle Scholar
  26. 22.
    Van Putten T, May PRA: Akinetic depression in schizophrenia. Arch Gen Psychiatry 35: 1101–1107, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • D. A. W. Johnson
    • 1
  1. 1.University Hospital of South ManchesterManchesterEngland

Personalised recommendations